Two imaging modalities predict progression from mild cognitive impairment to Lewy body dementia

Takeaway

  • People with mild cognitive impairment who have core clinical features of Lewy body dementia have imaging biomarker abnormalities that are linked to clinical phenotypes.

Why this matters

  • This novel study uses two imaging modalities to identify biomarkers that are sensitive to different pathologic processes in prodromal Lewy body dementia. The findings suggest that amyloid-β positron emission tomography and dopamine transporter imaging are complementary in characterizing clinical phenotypes of individuals at risk of progressing to Lewy body dementia.

  • The finding that amyloid-β positivity is linked to worse cognitive function highlights a potential therapeutic target for slowing the progression from prodromal to overt Lewy body dementia.